Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)

NCT07653477 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

956

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: UBT251 Injection 2.0 mg group
DRUG: UBT251 Injection 4.0 mg group
DRUG: UBT251 Injection 6.0 mg group
DRUG: Semaglutide Injection

Sponsor

The United Bio-Technology (Hengqin) Co., Ltd.